{"filing":{"accession_number":"0001193125-26-267862","cik":"0001662774","ticker":"QNCX","company_name":"Quince Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"d124733d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/d124733d8k.htm"},"events":[{"id":5380,"run_id":4714,"accession_number":"0001193125-26-267862","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 disclosure presents the final voting results from Quince Therapeutics' Annual Meeting of Stockholders held on June 11, 2026, covering five proposals: election of a Class I director (June Bray), approval of a reverse stock split amendment (1-for-10 to 1-for-100 ratio), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and adjournment authority. All proposals were approved by stockholders. The reverse stock split authorization is particularly material as it represents a significant corporate action that could affect share structure and investor holdings.","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6424,"accession_number":"0001193125-26-267862","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure presents the final voting results from Quince Therapeutics' Annual Meeting of Stockholders held on June 11, 2026, covering five proposals: election of a Class I director (June Bray), approval of a reverse stock split amendment (1-for-10 to 1-for-100 ratio), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and adjournment authority. All proposals were approved by stockholders. The reverse stock split authorization is particularly material as it represents a significant corporate action that could affect share structure and investor holdings.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:08:09.610996+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6424,"accession_number":"0001193125-26-267862","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure presents the final voting results from Quince Therapeutics' Annual Meeting of Stockholders held on June 11, 2026, covering five proposals: election of a Class I director (June Bray), approval of a reverse stock split amendment (1-for-10 to 1-for-100 ratio), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and adjournment authority. All proposals were approved by stockholders. The reverse stock split authorization is particularly material as it represents a significant corporate action that could affect share structure and investor holdings.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:08:09.610996+00:00","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-06-11"}]}